Inflammation sits at the heart of cardiometabolic disease. While GLP-1 receptor agonists are best known for improving glycemic control and supporting weight loss, emerging research suggests their role may extend further. Could the anti-inflammatory effects of GLP-1 therapies help explain some of the cardiovascular benefits observed in large outcome trials? …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.